2025-04-24-上交所-健康元药业集团股份有限公司2025年第一季度报告（英文版）_12页_258kb

报告摘要

Joincare Pharmaceutical Industry Co., Ltd. 2025 Q1 Quarterly Report Summary

Executive Warrant

The board of directors, supervisory board, directors, supervisors, and senior management warrant the authenticity, accuracy, and completeness of this quarterly report, assuming corresponding legal liability.

Financial Performance Highlights

Revenue & Profit: Total revenue for Q1 2025 was RMB 4.09 billion, declining by 5.77% YoY. Net profit attributable to shareholders decreased 0.91% to RMB 435.8 million. Adjusted net profit saw a slight decline of 0.93%. Basic earnings per share were RMB 0.23, down compared to RMB 0.24. ROA decreased by 0.16 percentage points.
Cash Flow: Operating cash flow fell to RMB 809.9 million (down 16.70%), while financing activities saw significant outflows of RMB -514.5 million.

Financial Statement Changes

Major changes include: a 52.55% increase in other current assets (new cash management launch), reduced financial liabilities due to forex contract settlement, deferred revenue recognition entries, and capital reserve reduction from share repurchase cancellation.

Shareholder Information

Total ordinary shares outstanding at the end of Q1 2025 were RMB 18.29 billion.
Top shareholder, Shenzhen BaiyeYuan Investment Co., Ltd., held 48.96% of the shares.